186 related articles for article (PubMed ID: 26622064)
1. KIT D816V-mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression.
Garcia-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Teodosio C; Sanchez-Muñoz L; Muñiz C; Muñoz-Gonzalez JI; Mayado A; Matito A; Caldas C; Morgado JM; Escribano L; Orfao A
Blood; 2016 Feb; 127(6):761-8. PubMed ID: 26622064
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CD34
Mayado A; Teodosio C; Dasilva-Freire N; Jara-Acevedo M; Garcia-Montero AC; Álvarez-Twose I; Sánchez-Muñoz L; Matito A; Caldas C; Muñoz-González JI; Henriques A; Sánchez-Gallego JI; Escribano L; Orfao A
Allergy; 2018 Jun; 73(6):1294-1304. PubMed ID: 29331029
[TBL] [Abstract][Full Text] [Related]
3. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
[TBL] [Abstract][Full Text] [Related]
4. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
[TBL] [Abstract][Full Text] [Related]
5. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
[TBL] [Abstract][Full Text] [Related]
6. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
[TBL] [Abstract][Full Text] [Related]
7. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
8. Origin of stem cells in the BM niche: new clues from mastocytosis.
Nemeth K; Mezey E
Blood; 2016 Feb; 127(6):670-2. PubMed ID: 26869307
[TBL] [Abstract][Full Text] [Related]
9. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.
Garcia-Montero AC; Jara-Acevedo M; Teodosio C; Sanchez ML; Nunez R; Prados A; Aldanondo I; Sanchez L; Dominguez M; Botana LM; Sanchez-Jimenez F; Sotlar K; Almeida J; Escribano L; Orfao A
Blood; 2006 Oct; 108(7):2366-72. PubMed ID: 16741248
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
[TBL] [Abstract][Full Text] [Related]
11. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
12. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
14. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
15. Frequency and prognostic impact of
Muñoz-González JI; Álvarez-Twose I; Jara-Acevedo M; Henriques A; Viñas E; Prieto C; Sánchez-Muñoz L; Caldas C; Mayado A; Matito A; Dasilva-Freire N; Orfao A; García-Montero AC
Blood; 2019 Aug; 134(5):456-468. PubMed ID: 31151985
[TBL] [Abstract][Full Text] [Related]
16. Adverse Prognostic Impact of the
Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
[TBL] [Abstract][Full Text] [Related]
17. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
18. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.
Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Class SV; Eisenwort G; Simonitsch-Klupp I; Esterbauer H; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
Haematologica; 2020; 105(2):366-374. PubMed ID: 31018976
[TBL] [Abstract][Full Text] [Related]
19. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
Wilson TM; Maric I; Simakova O; Bai Y; Chan EC; Olivares N; Carter M; Maric D; Robyn J; Metcalfe DD
Haematologica; 2011 Mar; 96(3):459-63. PubMed ID: 21134978
[TBL] [Abstract][Full Text] [Related]
20. Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.
Mayado A; Teodosio C; Garcia-Montero AC; Matito A; Rodriguez-Caballero A; Morgado JM; Muñiz C; Jara-Acevedo M; Álvarez-Twose I; Sanchez-Muñoz L; Matarraz S; Caldas C; Muñoz-González JI; Escribano L; Orfao A
Leukemia; 2016 Jan; 30(1):124-30. PubMed ID: 26153655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]